Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Literature DB >> 29236570

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Laura A Levit¹, Raymond P Perez¹, David C Smith¹, Richard L Schilsky¹, Daniel F Hayes¹, Julie M Vose¹.

Abstract

Mesh：

Substances：
Antineoplastic Agents

Year: 2017 PMID： 29236570 DOI： 10.1200/JCO.2017.75.8193

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

1. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group.

Authors: Caitlin W Elgarten; Joel C Thompson; Anne Angiolillo; Zhiguo Chen; Susan Conway; Meenakshi Devidas; Sumit Gupta; John A Kairalla; Jennifer L McNeer; Maureen M O'Brien; Karen R Rabin; Rachel E Rau; Susan R Rheingold; Cindy Wang; Charlotte Wood; Elizabeth A Raetz; Mignon L Loh; Sarah Alexander; Tamara P Miller
Journal: Pediatr Blood Cancer Date: 2022-09-09 Impact factor: 3.838

Review 2. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959

Review 3. Pharmacovigilance in oncology.

Authors: Paolo Baldo; Giulia Fornasier; Laura Ciolfi; Ivana Sartor; Sara Francescon
Journal: Int J Clin Pharm Date: 2018-08-01

4. Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials.

Authors: Jennifer G Le-Rademacher; Elizabeth M Storrick; Aminah Jatoi; Sumithra J Mandrekar
Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-05-27

5. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.

Authors: David Hsiehchen; Mary K Watters; Rong Lu; Yang Xie; David E Gerber
Journal: JAMA Netw Open Date: 2019-09-04

6. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.

Authors: Zahra Karimian; Sandra Mavoungou; Joe-Elie Salem; Florence Tubach; Agnès Dechartres
Journal: BMC Cancer Date: 2020-11-23 Impact factor: 4.430

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

1. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group.

Review 2. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Review 3. Pharmacovigilance in oncology.

4. Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials.

5. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.

6. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.

7. [Research Progress of Antitumor Pharmacovigilance].

8. Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer.

9. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials.

10. Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors.